STOCK TITAN
  1. Home
  2. Sec-filings
  3. ROIV
  4. [Form 4] Roivant Sciences Ltd. Insider Trading Activity

ROIV insider Venker exercises options, sells 125,667 shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Roivant Sciences (ROIV) — Form 4 insider transaction: President & Immunovant CEO Eric Venker reported option exercises and same‑day sales under a Rule 10b5‑1 plan. On 10/09/2025, he exercised 104,940 stock options at $15.85 (Code M) and sold 104,940 Common Shares at a weighted average price of $16.30 (Code S). On 10/13/2025, he exercised 20,727 options at $15.85 and sold 20,727 shares at a weighted average price of $16.25.

Following these transactions, beneficial ownership of Common Shares was 1,504,959 (direct). The options exercised were part of awards with a vesting commencement date of December 27, 2019, now fully vested, and an expiration date of March 31, 2026. The reported sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on March 28, 2025.

Positive

  • None.

Negative

  • None.

Insights

Routine 10b5-1 option exercises and matched sales; neutral.

The reporting officer executed option exercises at $15.85 and sold the same number of shares at weighted average prices of $16.30 and $16.25 on 10/09/2025 and 10/13/2025, respectively. These trades were conducted pursuant to a Rule 10b5-1 plan.

Form 4 filings of this type are administrative and typically neutral for the equity narrative. The filing lists post-transaction direct ownership of 1,504,959 common shares and notes that the options exercised were fully vested from a grant with a vesting commencement date of 12/27/2019.

Insider Venker Eric
Role President & Immunovant CEO
Sold 125,667 shs ($2.05M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 20,727 $0.00 --
Exercise Common Shares 20,727 $15.85 $329K
Sale Common Shares 20,727 $16.25 $337K
Exercise Stock Option (Right to Buy) 104,940 $0.00 --
Exercise Common Shares 104,940 $15.85 $1.66M
Sale Common Shares 104,940 $16.30 $1.71M
Holdings After Transaction: Stock Option (Right to Buy) — 851,383 shares (Direct); Common Shares — 1,525,686 shares (Direct)
Footnotes (1)
  1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Venker Eric
(Last) (First) (Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY
(Street)
LONDON X0 SW1H 0DB
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President & Immunovant CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 10/09/2025 M 104,940 A $15.85 1,609,899 D
Common Shares 10/09/2025 S 104,940 D $16.3(1) 1,504,959 D
Common Shares 10/13/2025 M 20,727 A $15.85 1,525,686 D
Common Shares 10/13/2025 S 20,727 D $16.25(1) 1,504,959 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $15.85 10/09/2025 M 104,940 (2) 03/31/2026 Common Stock 104,940 $0 872,110 D
Stock Option (Right to Buy) $15.85 10/13/2025 M 20,727 (2) 03/31/2026 Common Stock 20,727 $0 851,383 D
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
2. Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ROIV’s Eric Venker report on Form 4?

He exercised stock options and sold the same number of Common Shares in two tranches on 10/09/2025 and 10/13/2025 under a Rule 10b5-1 plan.

How many ROIV shares were sold by Eric Venker?

He sold 104,940 shares at a weighted average price of $16.30 and 20,727 shares at a weighted average price of $16.25.

What was the option exercise price in the ROIV Form 4?

The options were exercised at $15.85 per share (Code M).

How many ROIV shares does Venker own after the transactions?

Beneficial ownership of Common Shares was 1,504,959 (direct) following the reported transactions.

Were the sales pre-arranged under a trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

What are the key dates tied to the options in the filing?

Vesting commenced on December 27, 2019; the options are fully vested and expire on March 31, 2026.